Previously, our group demonstrated that tissue TMB (tTMB) estimated by a 422‐cancer‐gene panel (GeneseeqPrime) in NSCLC patients is associated with clinical benefit from anti‐PD‐(L)1 therapies.15 The gene discussed is CD274; the disease is non-small cell lung carcinoma.